Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_1

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

N/ANon-phased studies

1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (50.0%)

N/A1 (50.0%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

Evaluate the Effect of Tirazamine on Primary Liver Cancer.

NCT06848556

terminatednot_applicable

TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma

NCT02704130

completed

Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).

NCT03163186

Clinical Trials (3)

Showing 3 of 3 trials

NCT06848556Phase 1

Evaluate the Effect of Tirazamine on Primary Liver Cancer.

Terminated

NCT02704130Not Applicable

TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma

Terminated

NCT03163186

Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).

Completed

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3